Smee DF, Yamamoto JK, Warden DR, Diaz JC, Glanville A; International Conference on AIDS.
Int Conf AIDS. 1993 Jun 6-11; 9: 492 (abstract no. PO-B28-2141).
Utah State University, Logan.
Solutein is a composite of three venoms from the eastern water moccasin, Thai cobra and many-banded krait possessing neurological and hematological properties. Since 1986 Solutein is being used to treat HIV infected individuals at a clinic in Tijuana, Mexico. Blood work is performed either at UC Davis or clinical laboratories in Los Angeles. Solutein inhibits reverse transcriptase activity in a manner similar to heparin. Patients were started on a very low dose of Solutein, which was gradually increased as the patient developed immunotolerance. This protocol was not toxic and the only adverse reactions were soreness at the injection site during the first 1-2 months. No adverse effects on 30 blood parameters were noted. Patients responded by showing an increase in energy level, appetite, mental alertness, sleep pattern, and quality of life. Three of 4 patients analyzed showed a complete suppression of p24 antigen in serum after 3 months. After 1 month on Solutein, the body's immune system actively fought and reduced lymphadenopathy, which in some patients the effects were striking. T4+ cell counts stabilized and/or increased and T8+ cell counts went down in some patients, resulting in improvements in T4/T8 ratios. Our hypothesis is that non-specific vaccination with Solutein benefits HIV-infected patients.
Publication Types:
Keywords:
- AIDS Vaccines
- Acquired Immunodeficiency Syndrome
- Anti-HIV Agents
- CD4-Positive T-Lymphocytes
- Drug Therapy, Combination
- HIV
- HIV Antibodies
- HIV Antigens
- HIV Core Protein p24
- HIV Envelope Protein gp120
- HIV Infections
- HIV Seropositivity
- Humans
- Los Angeles
- Mexico
- RNA-Directed DNA Polymerase
- drug therapy
- immunology
- therapy
Other ID:
UI: 102205138
From Meeting Abstracts